A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help control chronic muscle inflammation in Duchenne muscular dystrophy (DMD), a severe condition that leads to muscle weakness and premature death. The study, published in PNAS, identifies new mechanisms that drive chronic muscle inflammation in a disease … Read more
For millions of people, losing muscle isn’t just about weakness; it’s about losing independence. Whether caused by Duchenne muscular dystrophy, aging or other degenerative conditions, muscle loss can make everyday activities – like walking, climbing stairs or even standing up – a daily struggle. But a recent discovery from researchers at the University of Houston … Read more
Patients with Duchenne muscular dystrophy (DMD) who received delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) showed long-term disease stabilization or slowed disease progression at 3 and 5 years of follow-up in data presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas.1,2 Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy approved for the … Read more
Adult men with Duchenne muscular dystrophy (DMD) were more than twice as likely to experience fractures compared with adult men without DMD in the UK, a recent study published in Muscle & Nerve found.1 However, less than half of the patient population had undergone bone monitoring, which suggests a need for better clinical guidance and … Read more